Biologics

Spine biologics is gaining more interest, and its innovation will be rooted in tailored patient care, Craig McMains, MD, said.

Atreon Orthopedics earned FDA 510(k) clearance for the BioCharge autobiologic matrix and launched the new product, according to a Feb. 20 news release. 

From new study findings to product launches, here are eight headlines to know in the orthobiologics space since Jan. 13:

Paul Fleissner, MD, of Fairlawn, Ohio-based Crystal Clinic Orthopaedic Center is the first surgeon to use the RejuvaKnee implant for meniscus repair.

The global spine biologics market is on pace to have a 17.51% compound annual growth rate from 2024 to 2034, according to a Jan. 31 news release from ResearchandMarkets.com.

Stem cell therapies can be effective for treating discogenic low back pain, according to a study published in the January 2025 issue of the International Journal of Spine Surgery.

Jamie Antoine, MD, of Seattle-based Proliance Surgeons performed the first case using CartiHeal's Agili-C implant in Washington state, according to a Jan. 27 LinkedIn post. 

Acuitive Technologies named Wayne Berberian, MD, as its chief medical officer, according to a Jan. 27 news release. 

LifeNet Health and Johnson & Johnson MedTech launched the PliaFX Flo demineralized bone matrix.

SurGenTec earned FDA 510(k) clearance for its OsteoFlo HydroFiber to be used as a stand-alone equivalent to autografts in spine surgeries.